Top Page
Next Science Ltd
(Sydney:NXS)
Next Science Ltd (NXS) vs. S&P 500 (SPY)
Next Science Ltd Business Overview & Revenue Model
Next Science Ltd Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 22.18M | 16.90M | ― | ― | ― | Gross Profit |
| 16.23M | 11.90M | ― | ― | ― | EBIT |
| -23.41M | -18.31M | -9.28M | -13.96M | -12.69M | EBITDA |
| -14.42M | -17.02M | ― | -13.18M | -12.11M | Net Income Common Stockholders |
| -24.51M | -18.30M | ― | -13.27M | -14.52M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 9.28M | 7.54M | ― | 15.24M | 16.92M | Total Assets |
| 17.90M | 18.37M | 13.67M | 23.49M | 22.71M | Total Debt |
| 961.97K | 1.80M | ― | ― | ― | Net Debt |
| -8.28M | -5.68M | ― | ― | -16.44M | Total Liabilities |
| 5.08M | 6.52M | ― | ― | ― | Stockholders Equity |
| 12.82M | 11.85M | 10.73M | 18.80M | 19.37M |
| Cash Flow | Free Cash Flow | |||
| -15.94M | -17.69M | ― | -14.03M | -14.11M | Operating Cash Flow |
| -22.09M | -17.01M | ― | -13.26M | -12.48M | Investing Cash Flow |
| -1.30M | -686.23K | ― | ― | ― | Financing Cash Flow |
| 20.11M | 14.78M | ― | 11.93M | 23.97M |
Next Science Ltd Technical Analysis
Next Science Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
58 Neutral | AU$64.47M | ― | -457.46% | ― | 21.93% | 10.34% | |
51 Neutral | $5.31B | 3.39 | -40.42% | 2.90% | 18.11% | 2.25% | |
47 Neutral | $90.77M | ― | -15.86% | ― | 12.93% | 62.47% | |
42 Neutral | AU$30.48M | ― | -7.59% | ― | 28.89% | 72.95% | |
39 Underperform | $29.22M | ― | -130.18% | ― | 3.37% | 47.32% |
Next Science Ltd Earnings Call Summary
Next Science Ltd Corporate Events
Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.
Next Science Limited has released its updated corporate governance statement, which is now available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. This move is expected to reinforce stakeholder confidence and align with industry standards, potentially impacting the company’s market perception positively.
Next Science Ltd, a company known for its innovative solutions in the medical technology industry, has released its 2024 Annual Report titled ‘A Year of Change, a Future of Growth.’ The report highlights significant developments and strategic shifts aimed at fostering growth and enhancing market positioning. The company’s focus on its XBIO® portfolio and recent studies underscores its commitment to advancing medical technology solutions. This announcement is likely to have implications for stakeholders as it signals a proactive approach towards future growth and operational enhancement.
Next Science Limited will release its first-quarter financial results for FY25 on April 24, 2025, followed by an investor webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman. This announcement is part of the company’s ongoing efforts to engage with the investment community and provide transparency about its financial performance. The results and subsequent discussion could impact stakeholders’ perceptions and the company’s market positioning, particularly given its focus on innovative medical technology solutions.
Next Science Limited has announced that its 2025 Annual General Meeting (AGM) will take place on May 9, 2025, at 10:00 am Sydney time. The AGM will be a hybrid event, allowing shareholders to attend either in person at the company’s Share Registrar office in Sydney or virtually via the Zoom platform. This meeting provides an opportunity for shareholders to engage with the company, ask questions, and participate in voting, reflecting Next Science’s commitment to transparent communication and stakeholder engagement.
Next Science Limited has announced a change in its securityholder registry services provider from MUFG Corporate Markets (AU) Limited to Automic Pty Ltd, effective from March 17, 2025. This change allows shareholders to manage their holdings through Automic’s secure online investor portal, enhancing the efficiency and accessibility of shareholder services. This strategic move is expected to streamline operations and improve stakeholder engagement.
Next Science Limited has announced that its 2025 Annual General Meeting will take place on Friday, 9 May 2025, at 10:00 am Sydney time. The company has set 19 March 2025 as the deadline for director nomination submissions. This announcement is part of the company’s ongoing efforts to engage with stakeholders and ensure transparent governance practices.
Next Science Limited, a company listed on the Australian Securities Exchange (ASX), has reported a change in the interests of a substantial holder. TIGA Trading Pty Ltd, along with associated entities, has increased its voting power in Next Science from 5.74% to 7.32% as of February 27, 2025. This change reflects a series of share acquisitions over several months, indicating a strategic move by TIGA Trading to strengthen its influence within the company.
Next Science Limited, a company listed on the ASX, has undergone a change in the interests of its substantial holder, Thorney Technologies Ltd. The notice indicates a significant increase in voting power from 5.74% to 7.32% as of February 27, 2025. This change reflects Thorney Technologies’ strategic adjustments in its investment in Next Science, potentially impacting the company’s shareholder dynamics and market perception.
Next Science Ltd has announced its FY24 results, highlighting significant advancements in its product offerings and market strategy. The company is leveraging its XBIO Platform and expanding its distribution through independent agency representatives to drive sales in surgical and wound care markets. With a focus on clinical data and regulatory approvals, Next Science aims to enhance its market penetration and scale operations, potentially impacting its industry positioning and stakeholder value.
Next Science Limited reported a 3% increase in revenue to US$22.8 million for FY24, driven by a significant rise in direct sales of its XPERIENCE™ product, which saw a 99% increase. The company achieved a gross profit of US$18.4 million, up 14%, and improved its gross margin to 81%. Operating expenses decreased by 15%, contributing to a 46% improvement in adjusted EBITDA loss. The company’s strategic shift to a more variable cost base and the expansion of its sales channels, including the addition of BLASTX™ to its surgical sales channel, have positioned it well for future growth.
Next Science Limited reported a 3% increase in revenues to USD 22.8 million for the year ending December 31, 2024, while also reducing its loss by 35% to USD 10.6 million. Despite the improved financial performance, the company did not declare any dividends, and its net tangible assets per ordinary security decreased significantly from 3.58 to 0.48 USD cents, indicating a challenging financial position. This financial update reflects the company’s ongoing efforts to strengthen its market position and improve its financial health, although challenges remain in achieving profitability.
Next Science Limited has received a Warning Letter from the US FDA following an inspection of its Jacksonville, Florida facility. The FDA identified issues related to marketing authorization, quality system regulation violations, and medical device reporting violations. Next Science has undertaken corrective actions and is committed to addressing the FDA’s concerns to ensure compliance. The company asserts that its products remain safe and effective for their intended uses.
Next Science Limited has announced that it will release its financial results for the fiscal year ending December 31, 2024, on February 28, 2025. The release will be followed by a webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman, aimed at engaging with the investment community. This announcement highlights the company’s transparency and engagement with stakeholders, potentially influencing investor confidence and market perception.
Next Science Ltd announced the cessation of 50,000 securities due to the lapse of conditional rights that were not or could not be satisfied. This development indicates potential implications for the company’s capital structure and may influence investor perception regarding the company’s operational strategies and market performance.